Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 2009; 101(02): 408-410
DOI: 10.1160/TH08-08-0543
DOI: 10.1160/TH08-08-0543
Letters to the Editor
Elevation of B cell-activating factor belonging to the tumour necrosis family family (BAFF) in haemophilia A patients with inhibitor
Financial support: This work was partially supported by grants from the Kurozumi Medical Foundation and Mitsubishi Pharma Research Foundation to YS, and by Health and Labor Sciences Research Grants (Research on Regulatory Science of Pharmaceuticals and Medical Devices, and Research on HIV/AIDS) from Ministry of Health, Labor, and Welfare, Japan to AY.Further Information
Publication History
Received:
23 August 2008
Accepted after minor revision:
12 January 2008
Publication Date:
23 November 2017 (online)
-
References
- 1 Qian J, Borovok M, Bi L. et al. Inhibitor antibody development and T cell response to human factor VIII in murine haemophilia A. Thromb Haemost 1999; 81: 240-244.
- 2 Lavigne-Lissalde G, Schved JF, Granier C. et al. Anti-factor VIII antibodies: a 2005 update. Thromb Haemost 2005; 94: 760-769.
- 3 Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2002; 2: 465-475.
- 4 Dillon SR, Gross JA, Ansell SM. et al. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006; 5: 235-246.
- 5 Bischof D, Elsawa SF, Mantchev G. et al. Selective activation of TACI by syndecan-2. Blood 2006; 107: 3235-3242.
- 6 Toubi E, Gordon S, Kessel A. et al. Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with auto-immunity. J Autoimmun 2006; 27: 134-139.
- 7 Lesley R, Xu Y, Kalled SL. et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004; 20: 441-453.
- 8 Thien M, Phan TG, Gardam S. et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20: 785-798.
- 9 Bosello S, Pers JO, Rochas C. et al. BAFF and rheumatic autoimmune disorders: implications for disease management and therapy. Int J Immunopathol Pharmacol 2007; 20: 1-8.
- 10 Groom J, Kalled SL, Cutler AH. et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren’s syndrome. J Clin Invest 2002; 109: 59-68.
- 11 Migita K, Abiru S, Maeda Y. et al. Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum Immunol 2007; 68: 586-591.
- 12 Hausl C, Maier E, Schwarz HP. et al. Long-term persistence of anti-factor VIII antibody-secreting cells in haemophilic mice after treatment with human factor VIII. Thromb Haemost 2002; 87: 840-845.
- 13 Castigli E, Scott S, Dedeoglu F. et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA 2004; 101: 3903-3908.
- 14 Mathias M, Khair K, Hann I. et al. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia. Br J Haematol 2004; 125: 366-368.
- 15 Carcao M, St Louis J, Poon MC. et al. Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience. Haemophilia 2006; 12: 7-18.
- 16 Collins PW. Treatment of acquired haemophilia A. J Thromb Haemost 2007; 5: 893-900.
- 17 Cohen SB. Updates from B cell trials: efficacy. J Rheumatol (Suppl) 2006; 77: 12-17.